• Abouljoud M, Yoshida A, Kim D, Jerius J, Arenas J, Raoufi M, Brown K, Moonka D 2005 Transjugular intrahepatic portosystemic shunts for refractory ascites after liver transplantation. Transplant. Proc. 37: 1248-1250. *

• Abraham C, Hart J, Locke SM, Baker AL 2008 A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 172-176. *

• Ackermann D, Mordasini D, Cheval L, Imbert-Teboul M, Vogt B, Doucet A 2007 Sodium retention and ascites formation in a cholestatic mice model: role of aldosterone and mineralocorticoid receptor? Hepatology 46: 173-179. *

• Adler M, Bourgeois N, van de Stadt J, Gelin M 1992 A Pugh score of 8 adequately selects patients with parenchymal cirrhosis for liver transplantation. Transpl. Int. 5 Suppl. 1: S175-S178.

• Agarwal S, Joyner KA Jr, Swaim MW 2000 Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am. J. Gastroenterol. 95: 3218-3224. *

• Ahishali E, Pinarbasi B, Akyuz F, Ibrisim D, Kaymakoglu S, Mungan Z 2007 A case of Aeromonas hydrophila enteritis in the course of ulcerative colitis. Eur. J. Intern. Med. 18: 430-431.

• Akcam M, Artan R, Yilmaz A, Cig H, Aksoy NH 2005 Abdominal tuberculosis in adolescents. Difficulties in diagnosis. Saudi Med. J. 26: 122-126.

• Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA 2006 Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J. Hepatol. 45: 575-583. *

• Al-Mukhaizeem KA, Rosenberg A, Sherker AH 2004 Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am. J. Hematol. 75: 225-230. *

• Alaish SM, Torres M, Ferlito M, Sun CC, De Maio A 2005 The severity of cholestatic injury is modulated by the genetic background. Shock 24: 412-416. *

• Alam I, Bass NM, Bacchetti P, Gee L, Rockey DC 2000 Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am. J. Gastroenterol. 95: 199-203. *

• Albillos A, Banares R, Gonzalez M, Catalina MV, Molinero LM 2005 A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J. Hepatol. 43: 990-996. *

• Albillos A, de-la-Hera A, Alvarez-Mon M 2004 Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 363: 1608-1610. *

• Aldersley MA, O'Grady JG 1995 Hepatic disorders. Features and appropriate management. Drugs 49: 83-102.

• Aliaga L, Mediavilla JD, Omar M, Zozaya JM, Prieto J 1995 Directional velocity of the arterial flow, systemic vascular resistance and urinary excretion of sodium in cirrhotic patients. Presse. Med. 24: 758-762.

• Alnounou M, Munoz SJ 2006 Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100. *

• Amarapurkar DN, Patel ND, Rane PS 2008 Diagnosis of Crohn's disease in India where tuberculosis is widely prevalent. World J. Gastroenterol. 14: 741-746. *

• Amarapurkar DN, Punamiya S, Patel ND 2006 An experience with covered transjugular intrahepatic portosystemic shunt for refractory ascites from western India. Ann. Hepatol. 5: 103-108. *

• Angeli P, Albino G, Carraro P, Dalla Pria M, Merkel C, Caregaro L, De Bei E, Bortoluzzi A, Plebani M, Gatta A 1996 Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology 23: 264-273. *

• Angeli P, Wong F, Watson H, Gines P 2006 Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 44: 1535-1542. *

• Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, Pichler L, Wichlas M, Kreil A, Schmid M, Ferlitsch A, Lipinski E, Brunner H, Lammer J, Ferenci P, Gangl A, Peck-Radosavljevic M 2003 Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 52: 879-885. *

• Araki Y, Sakaguchi C, Ishizuka I, Sasaki M, Tsujikawa T, Koyama S, Furukawa A, Fujiyama Y 2005 Budd-Chiari syndrome: a case with a combination of hepatic vein and superior vena cava occlusion. World J. Gastroenterol. 11: 3797-3799. *

• Arroyo V 2002 Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Ann. Hepatol. 1: 72-79. *

• Arroyo V, Colmenero J 2003 Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J. Hepatol. 38 Suppl. 1: S69-S89. *

• Arroyo V, Colmenero J 2003 Use of albumin in the management of patients with decompensated cirrhosis. An independent verdict. Dig. Liver Dis. 35: 668-672.

• Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ 2003 Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J. Lab. Clin. Med. 142: 385-390. *

• Attwell A, Ludkowski M, Nash R, Kugelmas M 2004 Treatment of Budd-Chiari syndrome in a Liver Transplant Unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation. Aliment. Pharmacol. Ther. 20: 867-873. *

• AydoGdu S, Ozgenc F, AtIk T, Unal F, Tokat Y, Yagci RV 2004 Biliary atresia in Turkish children. Pediatr. Int. 46: 158-161. *

• Bachet JB, Condat B, Hagege H, Plessier A, Consigny Y, Belghiti J, Valla D 2007 Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome. J. Hepatol. 46: 60-68. *

• Barnes DS 2002 Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm.

• Basaran A, Zafer Tuncer S 2007 Ascites is the primary cause of cancer antigen-125 (CA-125) elevation in systemic lupus erythematosus (SLE) patients with nephrotic syndrome. Med. Hypotheses 68: 197-201.

• Beckett GJ, Dewhurst N, Finlayson ND, Percy-Robb IW 1980 Weight loss in primary biliary cirrhosis. Gut 21: 734-737. *

• Ben-Ari Z 2004 Ascites after transplantation - a mystery. Liver Transpl. 10: 1221. *

• Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F 2003 Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52: 1355-1362. *

• Berber E, Rogers S, Siperstein A 2005 Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer. A prospective study. Surg. Endosc. 19: 710-714. *

• Bert F, Bellier C, Lassel L, Lefranc V, Durand F, Belghiti J, Mentre F, Fantin B 2005 Risk factors for Staphylococcus aureus infection in liver transplant recipients. Liver Transpl. 11: 1093-1099. *

• Bertrams A, Ziegler K 1991 Hepatocellular uptake of peptides by bile acid transporters: relationship of carrier-mediated transport of linear peptides with renin-inhibiting activity to multispecific bile acid carriers. Biochim. Biophys. Acta 1091: 337-348.

• Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G 2006 Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130: 1652-1660. *

• Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA 2005 Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 41: 32-39. *

• Blachar A, Federle MP, Brancatelli G 2001 Primary biliary cirrhosis: clinical, pathologic, and helical CT findings in 53 patients. Radiology 220: 329-336. *

• Blendis L 1999 Ascites and renal disorders in liver disease Gastroenterology 117: 1023-1024. *

• Blendis L 2005 Trial for treatment of refractory ascites TIPS the scales. Gastroenterology 128: 797-798. *

• Brigman C, Feranchak A 2006 Liver involvement in cystic fibrosis. Curr. Treat. Options Gastroenterol. 9: 484-496.

• Brinson RR, Curtis WD, Schuman BM, Mills LR 1988 Recovery from hepatic vein thrombosis (Budd-Chiari syndrome) complicating ulcerative colitis. Dig. Dis. Sci. 33: 1615-1620.

• Brostoff JM, Rashid S, McCrea D 2008 Primary biliary cirrhosis with a normal alkaline phosphatase: a case report. Cases J. 1: 33. *

• Brueck M, Runde T, Rauber K, Kramer W 2006 Portal and mesenteric venous thrombosis in inflammatory bowel disease treated by fibrinogen-guided thrombolysis with urokinase. Dtsch. Med. Wochenschr. 131: 84-88.

• Brunerova L, Bartakova H, Jankovska M, Cieslarova B, Hulek P, Kozak T, Andel M 2004 The Budd-Chiari syndrome in a patient with primary thrombocythemia treated with interferon alfa and transjugular portosystemic shunt. Cas. Lek. Cesk. 143: 198-201.

• Bugianesi E 2005 Late complications of NASH: a challenge for hepatologists. J. Hepatol. 42: 784-785.

• Burroughs AK, Patch D 1999 Transjugular intrahepatic portosystemic shunt. Semin. Liver Dis. 19: 457-473.

• Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ 1999 Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29: 664-669. *

• Campbell MS, Kotlyar DS, Brensinger CM, Lewis JD, Shetty K, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Reddy KR 2005 Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl. 11: 1048-1055. *

• Campos J, Gonzalez-Quintela A, Quinteiro C, Gude F, Perez LF, Torre JA, Vidal C 2005 The -159C/T polymorphism in the promoter region of the CD14 gene is associated with advanced liver disease and higher serum levels of acute-phase proteins in heavy drinkers. Alcohol. Clin. Exp. Res. 29: 1206-1213. *

• Cangemi JR, Wiesner RH, Beaver SJ, Ludwig J, MacCarty RL, Dozois RR, Zinsmeister AR, LaRusso NF 1989 Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 96: 790-794.

• Capron JP, Degott C, Bernuau J, Saint-Marc Girardin MF, Zafrani ES, Braillon A, Quenum C, Dhumeaux D, Benhamou JP 1983 Nodular regenerative hyperplasia of the liver. Study of 15 cases and review of the literature. Gastroenterol. Clin. Biol. 7: 761-769.

• Capuano G, Pomponi D, Iaccarino V, Budillon G 2004 An unusual case of ascites. Dig. Liver Dis. 36: 628-631.

• Carcopino X, Chaumoitre K, Shojai R, Akkawi R, Panuel M, Boubli L, D'Ercole C 2007 Foetal magnetic resonance imaging and echogenic bowel. Prenat. Diagn. 27: 272-278.

• Cardenas A, Bataller R, Arroyo V 2000 Mechanisms of ascites formation. Clin. Liver Dis. 4: 447-465.

• Cardenas A, Gines P 2001 Pathogenesis and treatment of fluid and electrolyte imbalance in cirrhosis. Semin. Nephrol. 21: 308-316.

• Casa C, Arnaud JP, Serra-Maudet V, Georgeac G, Kanane S, Ronceray J 1993 Mesocaval anastomosis in the treatment of recurring hemorrhage caused by portal hypertension. J. Chir. (Paris) 130: 517-521.

• Chaimovitz C, Rochman J, Eidelman S, Better OS 1977 Exaggerated natriuretic response to volume expansion in patients with primary biliary cirrhosis. Am. J. Med. Sci. 274: 173-178.

• Chan CW, Carpenter JR, Rigamonti C, Gunsar F, Burroughs AK 2005 Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model. Scand. J. Gastroenterol. 40: 1081-1089. *

• Chan CW, Carpenter JR, Rigamonti C, Gunsar F, Burroughs AK 2004 Survival following the development of ascites and/or oedema in primary biliary cirrhosis: a stage prognostic model. Gut 53: A84.

• Chan T, Palevsky HI, Miller WT 1988 Pulmonary hypertension complicating portal hypertension: findings on chest radiographs. AJR Am. J. Roentgenol. 151: 909-914. *

• Chapman RW 2003 The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17.

• Chen JY, Wang CM, Lu SC, Chou YH, Luo SF 2006 Association of apoptosis-related microsatellite polymorphisms on chromosome 1q in Taiwanese systemic lupus erythematosus patients. Clin. Exp. Immunol. 143: 281-287. *

• Chen MJ, Chu CH, Lin SC, Shih SC, Wang TE 2003 Eosinophilic gastroenteritis: clinical experience with 15 patients. World J. Gastroenterol. 9: 2813-2816. *

• Chen W, Gluud C 2003 Bile acids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2: CD003626. *

• Chesner IM, Muller S, Newman J 1986 Ulcerative colitis complicated by Budd-Chiari syndrome. Gut 27: 1096-1100. *

• Chou KT, Lee YC, Chen CW, Shih JF, Tung SM, Yang YT, Perng RP 2007 Lupus erythematosus (LE) cells in ascites: initial diagnosis of systemic lupus erythematosus by cytological examination: a case report. Clin. Rheumatol. 26: 1931-1933. *

• Choudhury J, Sanyal AJ 2003 Treatment of ascites. Curr. Treat. Options Gastroenterol. 6: 481-491.

• Christensen E, Altman DG, Neuberger J, De Stavola BL, Tygstrup N, Williams R 1993 Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. Gastroenterology 105: 1865-1876.

• Christensen E, Crowe J, Doniach D, Popper H, Ranek L, Rodes J, Tygstrup N, Williams R 1980 Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78: 236-246.

• Christensen E, Gunson B, Neuberger J 1999 Optimal timing of liver transplantation for patients with primary biliary cirrhosis: use of prognostic modelling. J. Hepatol. 30: 285-292. *

• Chu KM, Lee YT, Ng EK 2006 EUS could detect ascites missed by CT scan * Author's reply. Gut 55: 1524. *

• Chung H, Kudo M, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y 2006 A proposal of the modified liver damage classification for hepatocellular carcinoma. Hepatol. Res. 34: 124-129.

• Cohran VC, Heubi JE 2003 Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415.

• Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers Jr RL, Rosoff Jr L, Garcia-Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, et al 2005 Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 42: 1184-1193. *

• Combes B, Luketic VA, Peters MG, Zetterman RK, Garcia-Tsao G, Munoz SJ, Lin D, Flye N, Carithers RL Jr 2004 Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am. J. Gastroenterol. 99: 264-268. *

• Cross TJ, Berry PA, Akbar N, Wendon J, Thein SL, Harrison PM 2007 Sickle liver disease - an unusual presentation in a compound heterozygote for HbS and a novel beta-thalassemia mutation. Am. J. Hematol. 82: 852-854. *

• Crowe J, Christensen E, Doniach D, Popper H, Tygstrup N, Williams R 1985 Early features of primary biliary cirrhosis: an analysis of 85 patients. Am. J. Gastroenterol. 80: 466-468.

• Curgunlu A, Vural P, Canbaz M, Erten N, Karan MA, Tascioglu C 2005 Plasma nitrate/nitrite and endothelin-1 in patients with liver cirrhosis. J. Clin. Lab. Anal. 19: 177-181.

• Curro G, Jiao L, Scisca C, Baccarani U, Mucciardi M, Habib N, Navarra G 2008 Radiofrequency-assisted liver resection in cirrhotic patients with hepatocellular carcinoma. J. Surg. Oncol. Aug 5 [Epub ahead of print].

• Czaja AJ 2005 Autoimmune liver disease. Curr. Opin. Gastroenterol. 21: 293-299.

• Czaja AJ 2007 Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262.

• Czaja AJ, Wolf AM, Baggenstoss AH 1980 Clinical assessment of cirrhosis in severe chronic active liver disease: specificity and sensitivity of physical and laboratory findings. Mayo Clin. Proc. 55: 360-364.

• D'Amico G, Luca A, Morabito A, Miraglia R, D'amico M 2005 Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 129: 1282-1293. *

• Dalle I, Geboes K 2002 Vascular lesions of the gastrointestinal tract. Acta Gastroenterol. Belg. 65: 213-219.

• Davis GL, Czaja AJ, Ludwig J 1984 Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 87: 1222-1227.

• De las Heras D, Fernandez J, Gines P, Cardenas A, Ortega R, Navasa M, Barbera JA, Calahorra B, Guevara M, Bataller R, Jimenez W, Arroyo V, Rodes J 2003 Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology 38: 452-459. *

• de Man RA 1997 Severe hepatitis attributed to paroxetine (Seroxat). Ned. Tijdschr. Geneeskd. 141: 540-542.

• De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ 2000 Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 6: 309-316. *

• Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O 1994 Sclerosing cholangitis in children. J. Pediatr. 124: 49-56.

• Degre D, Bourgeois N, Boon N, Le Moine O, Louis H, Donckier V, El Nakadi I, Closset J, Lingier P, Vereerstraeten P, Gelin M, Adler M 2004 Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation. Transpl. Int. 17: 31-38.

• Deibert P, Konig D, Allgaier HP, Berg A 2007 Sport and the digestive system. Dtsch. Med. Wochenschr. 132: 155-160.

• DeLeve LD, Shulman HM, McDonald GB 2002 Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin. Liver Dis. 22: 27-42.

• Desai HG, Naik AS 2005 Acute viral E hepatitis with chronic liver disease (autoimmune hepatitis). Indian J. Med. Sci. 59: 113-115. *

• Deschenes M, Villeneuve JP, Dagenais M, Fenyves D, Lapointe R, Pomier-Layrargues G, Roy A, Willems B, Marleau D 1997 Lack of relationship between preoperative measures of the severity of cirrhosis and short-term survival after liver transplantation. Liver Transpl. Surg. 3: 532-537.

• Desmet VJ, Roskams T 2004 Cirrhosis reversal: a duel between dogma and myth. J. Hepatol. 40: 860-867. *

• Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK 2007 The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver Int. 27: 1402-1408. *

• Detry O, De Roover A, Coimbra C, Delwaide J, Szapiro D, Kaba A, Joris J, Damas P, Meurisse M, Honore P 2004 Autoimmune cirrhosis treated by liver transplantation using the right hepatic lobe from a living related donor. Rev. Med. Liege. 59: 69-74.

• Devarbhavi H, Kaese D, Williams AW, Rakela J, Klee GG, Kamath PS 2002 Cancer antigen 125 in patients with chronic liver disease. Mayo Clin. Proc. 77: 538-541. *

• Dhiman RK, Behera A, Chawla YK, Dilawari JB, Suri S 2007 Portal hypertensive biliopathy. Gut 56: 1001-1008. *

• Dolev E, Sandman-Goddard G 1989 Eosinophilic gastroenteritis. Harefuah. 116: 465-466.

• Doria C, Marino IR 2005 Bacteremia using the molecular adsorbent recirculating system in patients bridged to liver transplantation. Exp. Clin. Transplant. 3: 289-292.

• Dubaniewicz A, Dubaniewicz A 2003 Cholangiocarcinoma - bile ducts cancer. Wiad. Lek. 56: 57-60.

• Dudley F 2004 Management of refractory ascites. J. Gastroenterol. Hepatol. 19: S194-S199. *

• Dumortier J, Pianta E, Le Derf Y, Bernard P, Bouffard Y, Boucaud C, Sagnard P, Delafosse B, Boillot O 2005 Peritoneovenous shunt as a bridge to liver transplantation. Am. J. Transplant. 5: 1886-1892. *

• Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, Malinchoc M, Kamath PS, Shah V 2005 MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41: 353-358. *

• Ebrahimi Daryani N, Aghamohammadi A, Mousavi Mirkala MR, Bashashati M, Rezaei N, Haghpanah B, Hashtroudi AA, Sayyah A 2004 Gastrointestinal complications in two patients with common variable immunodeficiency. Iran. J. Allergy Asthma Immunol. 3: 149-152.

• Eckhoff DE, Pirsch JD, D'Alessandro AM, Knechtle SJ, Young CJ, Geffner SR, Belzer FO, Kalayoglu M 1995 Pretransplant status and patient survival following liver transplantation. Transplantation 60: 920-925.

• Efrati O, Barak A, Modan-Moses D, Augarten A, Vilozni D, Katznelson D, Szeinberg A, Yahav J, Bujanover Y 2003 Liver cirrhosis and portal hypertension in cystic fibrosis. Eur. J. Gastroenterol. Hepatol. 15: 1073-1078.

• Eriksson AS, Gretzer C, Wallerstedt S 2004 Elevation of cytokines in peritoneal fluid and blood in patients with liver cirrhosis. Hepatogastroenterology 51: 505-509.

• Esteva-Font C, Baccaro ME, Fernandez-Llama P, Sans L, Guevara M, Ars E, Jimenez W, Arroyo V, Ballarin JA, Gines P 2006 Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology 44: 1555-1563. *

• Evans LT, Kim WR, Poterucha JJ, Kamath PS 2003 Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 37: 897-901. *

• Farrell GC, Cooksley WG, Hart P, Powell LW 1978 Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. Gastroenterology 75: 580-688.

• Fartoux L, Serfaty L 2005 Liver cirrhosis in adults: etiology and specific treatments. Rev. Prat. 55: 1539-1548.

• Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, Salinas F, Dona S, Fagiuoli S, Sticca A, Zanus G, Cillo U, Frasson I, Destro C, Gatta A 2007 Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 45: 223-229. *

• Faust TW 1999 Budd-Chiari syndrome. Curr. Treat. Options Gastroenterol. 2: 491-504.

• Ferguson JW, Dover AR, Chia S, Cruden NL, Hayes PC, Newby DE 2006 Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 55: 542-546. *

• Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, Cardenas A, Guevara M, Sort P, Jimenez W, Bataller R, Arroyo V, Rodes J 2001 A prognostic model for predicting survival in cirrhosis with ascites. J. Hepatol. 34: 46-52. *

• Fernandez-Rodriguez CM, Romero J, Petros TJ, Bradshaw H, Gasalla JM, Gutierrez ML, Lledo JL, Santander C, Fernandez TP, Tomas E, Cacho G, Walker JM 2004 Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int. 24: 477-483. *

• Ferral H, Gamboa P, Postoak DW, Albernaz VS, Young CR, Speeg KV, McMahan CA 2004 Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology 231: 231-236. *

• Finegold MJ, Carpenter RJ 1982 Obliterative cholangitis due to cytomegalovirus: a possible precursor of paucity of intrahepatic bile ducts. Hum. Pathol. 13: 662-665.

• Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, Baldo V, Premoli A, Olivero F, Morello E, Durazzo M 2006 Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment. Pharmacol. Ther. 24: 1051-1057.

• Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J,Couzigou P, de Ledinghen V 2006 Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403-408. *

• Frances R, Chiva M, Sanchez E, Gonzalez-Navajas JM, Llobet T, Zapater P, Soriano G, Munoz C, Balanzo J, Perez-Mateo M, Song X, Guarner C, Such J 2007 Bacterial translocation is downregulated by anti-TNF-alpha monoclonal antibody administration in rats with cirrhosis and ascites. J. Hepatol. 46: 797-803. *

• Frances R, Munoz C, Zapater P, Uceda F, Gascon I, Pascual S, Perez-Mateo M, Such J 2004 Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 53: 860-864. *

• Franco J, Saeian K 1999 Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101.

• Frazer IH, Lichtenstein M, Andrews JT 1983 Pleuroperitoneal effusion without ascites. Med. J. Aust. 2: 520-521.

• Frey FJ 2006 Impaired 11beta-hydroxysteroid dehydrogenase contributes to renal sodium avidity in cirrhosis: hypothesis or fact? Hepatology 44: 795-801. *

• Friedman SL 2003 Liver fibrosis - from bench to bedside. J. Hepatol. 38 Suppl. 1: S38-S53. *

• Fukushima T, Dong L, Sakai T, Sawaki T, Miki M, Tanaka M, Masaki Y, Hirose Y, Kuwana M, Umehara H 2008 Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus 17: 210-214.

• Garcia-Compean D, Blanc P, Larrey D, Daures JP, Hirtz J, Mendoza E, Maldonado H, Michel H 2002 Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann. Hepatol. 1: 29-35. *

• Garcia-Tsao G 2006 Portal hypertension. Curr. Opin. Gastroenterol. 22: 254-262.

• Garcia-Tsao G 2004 Portal hypertension. Curr. Opin. Gastroenterol. 20: 254-263.

• Garcia-Tsao G 2003 Portal hypertension. Curr. Opin. Gastroenterol. 19: 250-258.

• Garcia-Tsao G 2005 Portal hypertension. Curr. Opin. Gastroenterol. 21: 313-322.

• Garcia-Tsao G 2002 Portal hypertension. Curr. Opin. Gastroenterol. 18: 351-359.

• Garcia-Tsao G 2001 Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 120: 726-748. *

• Geerts AM, Vanheule E, Praet M, Van Vlierberghe H, De Vos M, Colle I 2008 Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation. Int. J. Exp. Pathol. 89: 251-263.

• Gentilini P, Bernardi M, Bolondi L, Craxi A, Gasbarrinie G, Ideo G, Laffi G, La Villa G, Salerno F, Ventura E, Pulazzini A, Segantini L, Romanelli RG 2004 The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standards. Dig. Liver Dis. 36: 539-546.

• Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G 1999 Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J. Hepatol. 30: 639-645. *

• Gentilini P, Laffi G, La Villa G, Romanelli RG, Blendis LM 1999 Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication? J. Hepatol. 31: 1088-1097. *

• Gerbes AL, Gulberg V 2006 Progress in treatment of massive ascites and hepatorenal syndrome. World J. Gastroenterol. 12: 516-519. *

• Gerhardt T, Wolff M, Fischer HP, Sauerbruch T, Reichel C 2005 Pitfalls in the diagnosis of intestinal tuberculosis: a case report. Scand. J. Gastroenterol. 40: 240-243. *

• Giannini E, Romagnoli P, Tenconi GL, Botta F, Malfatti F, Chiarbonello B, Mamone M, Barreca T, Testa R 2004 High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: relationship with TNF-alpha levels. Dig. Dis. Sci. 49: 275-280. *

• Gines P 2003 Refractory ascites and hepatorenal syndrome. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 97-98. October 17 - 19. *

• Gines P, Arroyo V, Rodes J 1997 Pathophysiology, complications, and treatment of ascites. Clin. Liver Dis. 1: 129-155.

• Gines P, Cardenas A, Arroyo V, Rodes J 2004 Management of cirrhosis and ascites. N. Engl. J. Med. 350: 1646-1654. *

• Gines P, Guevara M, De Las Heras D, Arroyo V 2002 Review article: albumin for circulatory support in patients with cirrhosis. Aliment. Pharmacol. Ther. 16 Suppl. 5: 24-31.

• Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, Torres M, Humbert P, Rimola A, Llach J, et al 1988 Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94: 1493-1502.

• Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D; HypoCAT Study Investigators 2008 Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48: 204-213.

• Gluud C, Christensen E 2002 Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 1: CD000551. *

• Gong Y, Huang Z, Christensen E, Gluud C 2007 Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am. J. Gastroenterol. 102: 1799-1807. *

• Gong Y, Huang ZB, Christensen E, Gluud C 2008 Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD000551. *

• Gores GJ, Moore SB, Fisher LD, Powell FC, Dickson ER 1987 Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens. Hepatology 7: 889-892.

• Granzotto M, Drigo I, Candussio L, Rosati A, Bartoli F, Giraldi T, Decorti G 2004 Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. Cancer Lett. 205: 107-115. *

• Gross CR, Malinchoc M, Kim WR, Evans RW, Wiesner RH, Petz JL, Crippin JS, Klintmalm GB, Levy MF, Ricci P, Therneau TM, Dickson ER 1999 Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 29: 356-364. *

• Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R; Portal Hypertension Collaborative Group 2005 Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N. Engl. J. Med. 353: 2254-2261. *

• Gruttadauria S, Mandala' L, Miraglia R, Caruso S, Minervini MI, Biondo D, Volpes R, Vizzini G, Marsh JW, Luca A, Marcos A, Gridelli B 2007 Successful treatment of small-for-size syndrome in adult-to-adult living-related liver transplantation: single center series. Clin. Transplant. 21: 761-766. *

• Guarner C, Gonzalez-Navajas JM, Sanchez E, Soriando G, Frances R, Chiva M, Zapater P, Benlloch S, Munoz C, Pascual S, Balanzo J, Perez-Mateo M, Such J 2006 The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 44: 633-639. *

• Guevara M, Fernandez-Esparrach G, Alessandria C, Torre A, Terra C, Montana X, Piera C, Alvarez ML, Jimenez W, Gines P, Arroyo V 2004 Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 40: 646-651. *

• Guida M, Mandato VD, Di Spiezio Sardo A, Di Carlo C, Giordano E, Nappi C 2005 Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels. J. Endocrinol. Invest. 28: 827-830.

• Gur C, Ilan Y, Shibolet O 2004 Hepatic hydrothorax - pathophysiology, diagnosis and treatment - review of the literature. Liver Int. 24: 281-284. *

• Haagsma EB, Gips CH, Wesenhagen H, Van Imhoff GW, Krom RA 1985 Liver disease and its effect on haemostasis during liver transplantation. Liver 5: 123-128.

• Hagi A, Nakayama M, Miura Y, Yagasaki K 2007 Effects of a fish oil-based emulsion on rat hepatoma cell invasion in culture. Nutrition 23: 871-877. *

• Haliloglu N, Erden A, Erden I 2008 Primary biliary cirrhosis: evaluation with T2-weighted MR imaging and MR cholangiopancreatography. Eur. J. Radiol. Feb 28 [Epub ahead of print].

• Han SW, Kim GW, Lee J, Kim YJ, Kang YM 2005 Successful treatment with stent angioplasty for Budd-Chiari syndrome in Behcet's disease. Rheumatol. Int. 25: 234-237. *

• Hanif M, Raza J, Qureshi H, Issani Z 2004 Etiology of chronic liver disease in children. J. Pak. Med. Assoc. 54: 119-122.

• Harmanci O, Bayraktar Y 2007 Portal hypertension due to portal venous thrombosis: etiology, clinical outcomes. World J. Gastroenterol. 13: 2535-2540. *

• Harmon WA, Helman CA 1981 Eosinophilic gastroenteritis and ascites. J. Clin. Gastroenterol. 3: 371-373.

• Heidelbaugh JJ, Bruderly M 2006 Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am. Fam. Physician 74: 756-762. *

• Heidelbaugh JJ, Sherbondy M 2006 Cirrhosis and chronic liver failure: part II. Complications and treatment. Am. Fam. Physician 74: 767-776. *

• Henz S, Buhler H, Pirovino M 1995 Spontaneous bacterial peritonitis: diagnostic and prognostic aspects. Schweiz. Med. Wochenschr. 125: 2379-2386.

• Herold C, Ganslmayer M, Deynet C, Hahn EG, Schuppan D 2002 Quantitative testing of liver function compared to prognostic scores in patients with primary biliary cirrhosis. Liver 22: 159-165.

• Herve F, Heron F, Levesque H, Marie I 2006 Ascites as the first manifestation of polyarteritis nodosa. Scand. J. Gastroenterol. 41: 493-495. *

• Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA 2004 Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 40: 802-810. *

• Hiasa Y, Tokumoto Y, Furukawa S, Takeshita E, Matsui H, Michitaka K, Horiike N, Onji M 2003 Two cases of asymptomatic primary biliary cirrhosis with ascites. Nippon Shokakibyo Gakkai Zasshi 100: 1400-1404.

• Hinterhuber L, Graziadei IW, Kahler CM, Jaschke W, Vogel W 2004 Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin. Gastroenterol. Hepatol. 2: 1039-1042.

• Horak W 1977 Etiology and clinical aspects of liver cirrhosis. Z. Gesamte. Inn. Med. 32: 16-22.

• Huang J, He X, Chen G, Zhu X, Lu M, Wang G, Fu Y, Yang Y, Guan X 2002 Liver transplantation at the Sun Yat-Sen University of Medical Sciences in China. Chin. Med. J. (Engl.) 115: 543-548.

• Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, Chang FY, Lee SD 2005 Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J. Hepatol. 42: 826-832. *

• Hurwich DB, Lindor KD, Hay JE, Gross JB Jr, Kaese D, Rakela J 1993 Prevalence of peritonitis and the ascitic fluid protein concentration among chronic liver disease patients. Am. J. Gastroenterol. 88: 1254-1257.

• Iannitti DA, Henderson JM 1997 The role of surgery in the treatment of portal hypertension. Clin. Liver Dis. 1: 99-114, xi.

• Iannuzzi C, Cozzolino G, Negro G 1993 Elective cholecystectomy in selected cirrhotic patients. Acta Chir. Belg. 93: 147-150.

• Ijichi H, Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Yonemura Y, Maehara Y 2008 Successful management of chylous ascites after living donor liver transplantation with somatostatin. Liver Int. 28: 143-145. *

• Ikuhashi Y, Yoshida S, Kennedy S, Zondervan K, Takemura N, Deguchi M, Ohara N, Maruo T 2007 Vascular endothelial growth factor +936 C/T polymorphism is associated with an increased risk of endometriosis in a Japanese population. Acta Obstet. Gynecol. Scand. 86: 1352-1358.

• Inomata Y, Kiuchi T, Kim I, Uemoto S, Egawa H, Asonuma K, Fujita S, Hayashi M, Tanaka K 1999 Auxiliary partial orthotopic living donor liver transplantation as an aid for small-for-size grafts in larger recipients. Transplantation 67: 1314-1319.

• Invernizzi P, Battezzati PM, Crosignani A, Zermiani P, Bignotto M, Del Papa N, Zuin M, Podda M 1998 Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin. Exp. Immunol. 114: 448-454. *

• Isabel Fiel M, Thung SN, Hytiroglou P, Emre S, Schiano TD 2007 Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis. Am. J. Surg. Pathol. 31: 607-614.

• Ismail Y, Muhamad A 2003 Protean manifestations of gastrointestinal tuberculosis. Med. J. Malaysia 58: 345-349.

• Ito K, Shiraki K, Sakai T, Yoshimura H, Nakano T 2005 Portal hypertensive colopathy in patients with liver cirrhosis. World J. Gastroenterol. 11: 3127-3130. *

• Kalaitzakis E, Johansson JE, Bjarnason I, Bjornsson E 2006 Intestinal permeability in cirrhotic patients with and without ascites. Scand. J. Gastroenterol. 41: 326-330. *

• Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Christos P, Paraskevi K, Konstantinos P, Katsaraki A, Tsianos EV 2005 Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites. Dig. Dis. Sci. 50: 1771-1777. *

• Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, Patch D, Burroughs AK 2007 Transjugular liver biopsy - indications, adequacy, quality of specimens, and complications - a systematic review. J. Hepatol. 47: 284-294. *

• Kalambokis GN, Tsianos EV 2008 Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome. Hepatology 48: 686.

• Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR 2001 A model to predict survival in patients with end-stage liver disease. Hepatology 33: 464-470. *

• Kawasaki M, Yagasaki K, Miura Y, Funabiki R 2004 Comparison of the changes in lipid metabolism between hepatoma-bearing and lipopolysaccharide-treated rats. Biosci. Biotechnol. Biochem. 68: 72-78. *

• Kazemier G, Metselaar HJ, de Man RA, Tran TC, Groenland TH, Tilanus HW 2008 Liver transplantation with a living donor: the first 3 cases in Rotterdam. Ned. Tijdschr. Geneeskd. 152: 817-821.

• Keeffe EB, Davis GL 2004 Advances in Liver Disease: Highlights from the 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003. Rev. Gastroenterol. Disord. 4: 36-42. *

• Kelly DM, Demetris AJ, Fung JJ, Marcos A, Zhu Y, Subbotin V, Yin L, Totsuka E, Ishii T, Lee MC, Gutierrez J, Costa G, Venkataraman R, Madariaga JR 2004 Porcine partial liver transplantation: a novel model of the "small-for-size" liver graft. Liver Transpl. 10: 253-263. *

• Khan TT, Reddy KS, Johnston TD, Lo FK, Shedlofsky S, Grubb S, Ranjan D 2002 Transjugular intrahepatic portosystemic shunt migration in patients undergoing liver transplantation. Int. Surg. 87: 279-281.

• Kikuchi H, Katsuramaki T, Kukita K, Taketani S, Meguro M, Nagayama M, Isobe M, Mizuguchi T, Hirata K 2007 New strategy for the antifibrotic therapy with oral administration of FR260330 (a selective inducible nitric oxide synthase inhibitor) in rat experimental liver cirrhosis. Wound Repair Regen. 15: 881-888. *

• Kim JJ, Dasika NL, Yu E, Fontana RJ 2008 Transjugular intrahepatic portosystemic shunts in liver transplant recipients. Liver Int. 28: 240-248. *

• Kim NI, Jo YJ, Song MH, Kim SH, Kim TH, Park YS, Eom WY, Kim SW 2004 Clinical features of eosinophilic gastroenteritis. Korean J. Gastroenterol. 44: 217-223.

• King PD, Rumbaut R, Sanchez C 1996 Pulmonary manifestations of chronic liver disease. Dig. Dis. 14: 73-82.

• Kiyici M, Nak SG, Budak F, Gurel S, Oral B, Dolar E, Gulten M 2006 Lymphocyte subsets and cytokines in ascitic fluid of decompensated cirrhotic patients with and without spontaneous ascites infection. J. Gastroenterol. Hepatol. 21: 963-969. *

• Kochar N, Tripathi D, Ireland H, Redhead DN, Hayes PC 2006 Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut 55: 1617-1623. *

• Kogo M, Kano A, Kiuchi Y, Mitamura K, Yoneyama K 2007 Prognostic index for survival in patients after treatment for primary hepatocellular carcinoma. Dig. Dis. Sci. 52: 2444-2451. *

• Kojima K, Nagayama R, Hirama S, Maeda T, Takikawa H, Miyake K, Yamanaka M, Shiga J 1999 Epstein-Barr virus infection resembling autoimmune hepatitis with lactate dehydrogenase and alkaline phosphatase anomaly. J. Gastroenterol. 34: 706-712.

• Komatsu H, Inui A, Sogo T, Fujisawa T, Egawa H, Tanaka K 2005 Severe hypogammaglobulinemia associated with hepatic vein stenosis causes cytomegalovirus infection after living-related liver transplantation. Transpl. Infect. Dis. 7: 41-44. *

• Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC 2005 Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 11: 627-634. *

• Krige JE, Beckingham IJ 2001 ABC of diseases of liver, pancreas, and biliary system. Portal hypertension-2. Ascites, encephalopathy, and other conditions. BMJ 322: 416-418. *

• Kuiper JJ, de Man RA, van Buuren HR 2007 Review article: management of ascites and associated complications in patients with cirrhosis. Aliment. Pharmacol. Ther. 26 Suppl. 2: 183-193. *

• Kumagi T, Heathcote JE 2008 Primary biliary cirrhosis. Orphanet J. Rare Dis. 3: 1. *

• Kuri K, Lee M 1994 Eosinophilic gastroenteritis manifesting with ascites. South. Med. J. 87: 956-957.

• Kuroda Y, Ono N, Akaogi J, Nacionales DC, Yamasaki Y, Barker TT, Reeves WH, Satoh M 2006 Induction of lupus-related specific autoantibodies by non-specific inflammation caused by an intraperitoneal injection of n-hexadecane in BALB/c mice. Toxicology 218: 186-196. *

• Laffi G, Gentilini P, Romanelli RG, La Villa G 2003 Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. Dig. Liver Dis. 35: 660-663.

• Lake AM 2004 Allergic bowel disease. Adolesc. Med. Clin. 15: 105-117, ix-x.

• Lakshmi MV, Sridharan GV, Butterworth D 1993 Gallstone cirrhosis: are we only seeing the tip of the iceberg? Br. J. Clin. Pract. 47: 164-165.

• Lamireau T, Martin S, Lallier M, Marcotte JE, Alvarez F 2006 Liver transplantation for cirrhosis in cystic fibrosis. Can. J. Gastroenterol. 20: 475-478.

• Lasker JN, Sogolow ED, Sharim RR 2005 The role of an online community for people with a rare disease: content analysis of messages posted on a primary biliary cirrhosis mailinglist. J. Med. Internet Res. 7: e10.

• Lau A, Bay C, Nadir A 2004 TIPS versus paracentesis for the treatment of refractory ascites. Hepatology 40: 1476. *

• Lazaridis KN, Lindor KD 1999 Primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 2: 473-480.

• Le Connie D, Nguyen H 2004 Eosinophilic gastroenteritis, ascites, and pancreatitis: a case report and review of the literature. South. Med. J. 97: 905-906.

• Lech T, Hydzik P, Kosowski B 2007 Significance of copper determination in late onset of Wilson's disease. Clin. Toxicol. (Phila.) 45: 688-694.

• Lee JU, Kim YH, Lee SY, Kim KH, Chung CH, Kim KH, Son HJ, Rhee PL, Kim JJ, Rhee JC 2004 Dose ascites mean more severe Crohn's disease? Korean J. Gastroenterol. 43: 304-309.

• Lee M, Hodges WG, Huggins TL, Lee EL 1996 Eosinophilic gastroenteritis. South. Med. J. 89: 189-194.

• Lee S, Son SC, Han MJ, Kim WJ, Kim SH, Kim HR, Jeon WK, Park KH, Shin MG 2008 Increased intestinal macromolecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites. World J. Gastroenterol. 14: 3884-3890. *

• Leiva JG, Salgado JM, Estradas J, Torre A, Uribe M 2007 Pathophysiology of ascites and dilutional hyponatremia: contemporary use of aquaretic agents. Ann. Hepatol. 6: 214-221. *

• Lenaerts A, Codden T, Meunier JC, Henry JP, Ligny G 2006 Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology 44: 844-849. *

• Leonis MA, Balistreri WF 2008 Evaluation and management of end-stage liver disease in children. Gastroenterology 134: 1741-1751. *

• Leuschner U, Manns MP, Eisebitt R 2005 Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis. Z. Gastroenterol. 43: 1051-1059.

• Levy C, Lindor KD 2003 Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37. *

• Levy M, Wexler MJ, Fechner C 1983 Renal perfusion in dogs with experimental hepatic cirrhosis: role of prostaglandins. Am. J. Physiol. 245: F521-F529.

• Lin CH, Yu JC, Chen TW, Chan DC, Chen CJ, Hsieh CB 2005 Sclerosing encapsulating peritonitis in a liver transplant patient: a case report. World J. Gastroenterol. 11: 5412-5413. *

• Lindor KD 1997 Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N. Engl. J. Med. 336: 691-695. *

• Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM, et al 1994 Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106: 1284-1290.

• Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF 1991 The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 86: 57-61.

• Liu H, Gaskari SA, Lee SS 2006 Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J. Gastroenterol. 12: 837-842. *

• Llado L, Figueras J, Comi S, Torras J, Serrano T, Castellote J, Jaurrieta E 2004 Haemophagocytic syndrome after liver transplantation in adults. Transpl. Int. 17: 221-223.

• Loomba V, Pawar G, Dhar KL, Setia MS 1995 Serum zinc levels in hepatic encephalopathy. Indian J. Gastroenterol. 14: 51-53.

• Lopez MJ, Lee YM 2005 Primary sclerosing cholangitis and primary biliary cirrhosis. The American College of Gastroenterology (http://www.acg.gi.org/patients/gihealth/pdf/sclerosing.pdf). *

• Lopez-Mendez E, Chavez-Tapia NC, Avila-Escobedo L, Cabrera-Aleksandrova T, Uribe M 2006 Early experience of Budd-Chiari syndrome treatment with transjugular intrahepatic portosystemic shunt. Ann. Hepatol. 5: 157-160. *

• Lyngbaek S, Adamsen S, Aru A, Bergenfeldt M 2006 Recurrent acute pancreatitis due to eosinophilic gastroenteritis. Case report and literature review. JOP 7: 211-217.

• Mahl TC, Shockcor W, Boyer JL 1994 Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J. Hepatol. 20: 707-713.

• Maier KP 1996 Current diagnosis of chronic nonviral hepatitis. Schweiz. Rundsch. Med. Prax. 85: 1507-1512.

• Mandell MS, Lezotte D, Kam I, Zamudio S 2002 Reduced use of intensive care after liver transplantation: patient attributes that determine early transfer to surgical wards. Liver Transpl. 8: 682-687. *

• Maor Y 2005 The use of albumin in patients with decompensated cirrhosis: the case in favor. Isr. Med. Assoc. J. 7: 115-118.

• Marbello L, Anghilieri M, Nosari A, Minola E, Cairoli R, Ricci F, Morra E 2004 Aggressive systemic mastocytosis mimicking sclerosing cholangitis. Haematologica 89: ECR35. *

• Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, Loguercio C, Apolone G, Niero M, Abbiati R; Italian Study Group for quality of life in cirrhosis 2001 Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 120: 170-178. *

• Marta S, Ewa NM, Miroslaw S, Marek S, Krzysztof L, Jan Z 2008 The diagnostic problems in patient with ascites, elevated Ca 125 level and autoantibodies against nuclear antigens and smooth muscle antigens mimicking advanced ovarian carcinoma - case study. Ginekol. Pol. 79: 375-377.

• Martinez Torrente F, Orts Castro A, Garcia-Montoto F, Perez-Cerda F 2005 Patient with right ventricular arrhythmogenic dysplasia, ascites and ulcerative colitis: anesthetic management during major abdominal surgery. Rev. Esp. Anestesiol. Reanim. 52: 631-633.

• Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Gloria H, Marinho R, Tavora I, Ramalho F, de Moura MC 2006 Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 26: 680-687. *

• Mascarenhas MR 2003 Treatment of gastrointestinal problems in cystic fibrosis. Curr. Treat. Options Gastroenterol. 6: 427-441.

• McCormick A, Sultan J 2005 Liver transplantation - patient selection and timing. Med. J. Malaysia 60 Suppl. B: 83-87.

• Meddings J 2008 The significance of the gut barrier in disease. Gut 57: 438-440.

• Meneu-Diaz JC, Moreno Gonzalez E, Moreno Elola-Olaso A, Lopez EV, Nuno Vazquez J, Jimenez C, Turrion V, Loinaz C, Gomez R, Abradelo M 2003 Liver recipients undergoing hepatic transplantation and subsequent retransplantation: a comparison between clinical characteristics. Hepatogastroenterology 50: 2143-2148.

• Michaels A, Levy C 2008 The medical management of primary sclerosing cholangitis. Medscape J. Med. 10: 61.

• Michl P, Gulberg V, Bilzer M, Waggershauser T, Reiser M, Gerbes AL 2000 Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: effects in patients with organic or functional renal failure. Scand. J. Gastroenterol. 35: 654-658. *

• Mieli-Vergani G, Vergani D 2004 Approach to a child with chronic liver disease. J. Gastroenterol. Hepatol. 19: S377-S378. *

• Mieli-Vergani G, Vergani D 2004 Liver transplantation in metabolic liver diseases. J. Gastroenterol. Hepatol. 19: S396-S397. *

• Mindikoglu AL, Anantharaju A, Hartman GG, Li SD, Villanueva J, Van Thiel DH 2003 Prochlorperazine-induced cholestasis in a patient with alpha-1 antitrypsin deficiency. Hepatogastroenterology 50: 1338-1340.

• Mitchell A, Adams LA, Macquillan G, Tibballs J, Vanden Driesen R, Delriviere L 2008 Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl. 14: 210-213.

• Moller JM, Santoni-Rugiu E, Chabanova E, Logager V, Hansen AB, Thomsen HS 2007 Magnetic resonance imaging with liver-specific contrast agent in primary amyloidosis and intrahepatic cholestasis. Acta Radiol. 48: 145-149.

• Montano-Loza A, Vazquez-Ballesteros E, Meza-Junco J, Villalobos-Zapata I, Olivera-Martinez M 2006 Seropositivity for Chlamydia pneumoniae in patients with primary biliary cirrhosis. Gastroenterol. Hepatol. 29: 113-117.

• Montano-Loza AJ, Carpenter HA, Czaja AJ 2008 Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am. J. Gastroenterol. 103: 1944-1951. *

• Moore KP, Aithal GP 2006 Guidelines on the management of ascites in cirrhosis. Gut 55 Suppl. 6: vi1-vi12. *

• Mor A, Gal R, Livneh A 2003 Abdominal and digestive system associations of familial Mediterranean fever. Am. J. Gastroenterol. 98: 2594-2604. *

• Moreau R, Delegue P, Pessione F, Hillaire S, Durand F, Lebrec D, Valla DC 2004 Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int. 24: 457-464. *

• Moreno R, Lardennois C, Drouin-Garraud V, Verspyck E, Marret S, Laquerriere A 2008 Prenatal revelation of Niemann-Pick disease type C in siblings. Acta Paediatr. 97: 1136-1139.

• Morioka D, Egawa H, Kasahara M, Jo T, Sakamoto S, Ogura Y, Haga H, Takada Y, Shimada H, Tanaka K 2007 Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver Transpl. 13: 80-90. *

• Moseley RH 2007 Liver and biliary tract disorders. Curr. Opin. Gastroenterol. 23: 217-220.

• Muller CA, Belyaev O, Appelros S, Buchler M, Uhl W, Borgstrom A 2008 Dexamethasone affects inflammation but not trypsinogen activation in experimental acute pancreatitis. Eur. Surg. Res. 40: 317-324.

• Nagata Y, Uto H, Hasuike S, Ido A, Hayashi K, Eto T, Hamakawa T, Tanaka K, Tsubouchi H 2003 Bridging use of plasma exchange and continuous hemodiafiltration before living donor liver transplantation in fulminant Wilson's disease. Intern. Med. 42: 967-970. *

• Nagi B, Rana SS, Kochhar R, Bhasin DK 2006 Sonoenteroclysis: a new technique for the diagnosis of small bowel diseases. Abdom. Imaging 31: 417-424. *

• Natarajan SK, Basivireddy J, Ramachandran A, Thomas S, Ramamoorthy P, Pulimood AB, Jacob M, Balasubramanian KA 2006 Renal damage in experimentally-induced cirrhosis in rats: role of oxygen free radicals. Hepatology 43: 1248-1256. *

• Nava VE, Cohen P, Bishop M, Fowler D, Jaffe ES, Ozdemirli M 2007 Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 31: 476-480.

• Navasa M, Forns X, Sanchez V, Andreu H, Marcos V, Borras JM, Rimola A, Grande L, Garcia-Valdecasas JC, Granados A, Rodes J 1996 Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrhosis after liver transplantation. J. Hepatol. 25: 129-134. *

• Nazareno J, Taves D, Preiksaitis HG 2006 Metastatic breast cancer to the gastrointestinal tract: a case series and review of the literature. World J. Gastroenterol. 12: 6219-6224. *

• Neuberger J 2003 Primary sclerosing cholangitis: indications for transplantation and recurrence. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 93-94. October 15-16. *

• Neuberger J 2004 Liver transplantation for autoimmune liver diseases. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 82-83. *

• Neuberger J 2003 Liver transplantation for cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 113-121.

• Neuberger J, Gunson B, Komolmit P, Davies MH, Christensen E 1999 Pretransplant prediction of prognosis after liver transplantation in primary sclerosing cholangitis using a Cox regression model. Hepatology 29: 1375-1379. *

• Ng VL, Balistreri WF 2005 Treatment options for chronic cholestasis in infancy and childhood. Curr. Treat. Options Gastroenterol. 8: 419-430.

• Nielsen DL 2004 Mechanisms and functional aspects of multidrug resistance in Ehrlich ascites tumour cells. Dan. Med. Bull. 51: 393-414. *

• Nolte W, Figulla HR, Ringe B, Wiltfang J, Munke H, Hartmann H, Pausch J, Ramadori G 1997 Refractory hydrothorax in primary biliary cirrhosis: successful treatment with transjugular intrahepatic portosystemic stent shunt. Dtsch. Med. Wochenschr. 122: 1275-1280.

• Nousbaum JB, Cadranel JF, Nahon P, Khac EN, Moreau R, Thevenot T, Silvain C, Bureau C, Nouel O, Pilette C, Paupard T, Vanbiervliet G, Oberti F, Davion T, Jouannaud V, Roche B, Bernard PH, Beaulieu S, Danne O, Thabut D, Chagneau-Derrode C, et al 2007 Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology 45: 1275-1281. *

• Nozue T, Kobayashi A, Uemasu F, Takagi Y, Endoh H, Sako A 1995 Plasma endothelin-1 levels of children with cirrhosis. J. Pediatr. Gastroenterol. Nutr. 21: 220-223.

• Nyblom H, Bjornsson E, Simren M, Aldenborg F, Almer S, Olsson R 2006 The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int. 26: 840-845. *

• O'Leary JG, Lepe R, Davis GL 2008 Indications for liver transplantation. Gastroenterology 134: 1764-1776. *

• Owczarek D, Garlicka M, Pierzchala-Koziec K, Skulina D, Szulewski P 2003 Met-enkephalin plasma concentration and content in liver tissue in patients with primary biliary cirrhosis. Przegl. Lek. 60: 461-466.

• Owen CA Jr 1980 Copper and hepatic function. Ciba Found. Symp. 79: 267-282.

• Paredes AH, Lewis JH 2007 Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann. Pharmacother. 41: 880-884.

• Pares A, Rodes J 2003 Natural history of primary biliary cirrhosis. Clin. Liver Dis. 7: 779-794.

• Parsi MA, Atreja A, Zein NN 2004 Spontaneous bacterial peritonitis: recent data on incidence and treatment. Cleve. Clin. J. Med. 71: 569-576. *

• Pasha T, Heathcote J, Gabriel S, Cauch-Dudek K, Jorgensen R, Therneau T, Dickson ER, Lindor KD 1999 Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 29: 21-26. *

• Paskonis M, Jurgaitis J, Mehrabi A, Kashfi A, Fonouni H, Strupas K, Buchler MW, Kraus TW 2006 Surgical strategies for liver transplantation in the case of portal vein thrombosis - current role of cavoportal hemitransposition and renoportal anastomosis. Clin. Transplant. 20: 551-562. *

• Pelizzo G, Codrich D, Zennaro F, Dell'oste C, Maso G, D'Ottavio G, Schleef J 2008 Prenatal detection of the cystic form of meconium peritonitis: no issues for delayed postnatal surgery. Pediatr. Surg. Int. 24: 1061-1065.

• Penketh AR, Wise A, Mearns MB, Hodson ME, Batten JC 1987 Cystic fibrosis in adolescents and adults. Thorax 42: 526-532. *

• Pepels MJ, Peters FP, Mebis JJ, Ceelen TL, Hoofwijk AG, Erdkamp FL 2006 Sclerosing peritonitis: an unusual cause of ascites in a patient with systemic lupus erythematosus. Neth. J. Med. 64: 346-349. *

• Perez Fernandez T, Lopez Serrano P, Tomas E, Gutierrez M, Lledo J, Cacho G, Santander C, Fernandez Rodriguez C 2004 Diagnostic and therapeutic approach to cholestatic liver disease. Rev. Esp. Enferm. Dig. 96: 60-73.

• Perkins JD 2008 Treatment of small-for-size syndrome. Liver Transpl. 14: 571-575.

• Piazzese E, Montalti R, Beltempo P, Bertelli R, Puviani L, Pacile V, Nardo B, Cavallari A 2004 Incidence, predisposing factors, and results of surgical treatment of incisional hernia after orthotopic liver transplantation. Transplant. Proc. 36: 3097-3098. *

• Pilati G, Villecco AS, Allegro G 1985 Eosinophilic gastroenteritis simulating ascites (eosinophilic ascites). Presentation of a case and review of the literature. Minerva Med. 76: 2319-2321.

• Pomier-Layrargues P 2004 Hepatic venous pressure gradient measurement: is it mandatory in the management of portal hypertension? J. Gastroenterol. Hepatol. 19: S158-S161. *

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP 2005 Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16. *

• Poupon R 2004 Treatment of primary biliary cirrhosis and overlap syndromes: current standards. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 77-78. *

• Poupon RE, Balkau B, Eschwege E, Poupon R 1991 A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N. Engl. J. Med. 324: 1548-1554.

• Poupon RE, Poupon R, Balkau B 1994 Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N. Engl. J. Med. 330: 1342-1347.

• Poynard T, Zourabichvili O, Hilpert G, Naveau S, Poitrine A, Benatar C, Chaput JC 1984 Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology 4: 324-327.

• Quack I, Sellin L, Buchner NJ, Theegarten D, Rump LC, Henning BF 2005 Eosinophilic gastroenteritis in a young girl - long term remission under Montelukast. BMC Gastroenterol. 5: 24. *

• Rafeey M, Kianrad M, Hasani A 2007 Autoimmune hepatitis in Iranian children. Indian J. Gastroenterol. 26: 11-13. *

• Ramirez MJ, Titos E, Claria J, Navasa M, Fernandez J, Rodes J 2004 Increased apoptosis dependent on caspase-3 activity in polymorphonuclear leukocytes from patients with cirrhosis and ascites. J. Hepatol. 41: 44-48. *

• Ramkumar D, Schulze KS 2003 Gastroduodenal motility. Curr. Opin. Gastroenterol. 19: 540-545.

• Raskopf E, Dzienisowicz C, Hilbert T, Rabe C, Leifeld L, Wernert N, Sauerbruch T, Prieto J, Qian C, Caselmann WH, Schmitz V 2005 Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. Hepatology 41: 1233-1240. *

• Rav-Acha M, Gur C, Ilan Y, Verstandig A, Eid A 2004 Budd-Chiari syndrome: updated treatment modalities. Harefuah. 143: 372-376, 389.

• Resnick D, Krinsky GA, Lavelle MT, Lee VS, Keogan MT, Morrin MM 2002 Do patients with primary sclerosing cholangitis have a greater frequency of pancreatic abnormalities at MRI than patients with other liver diseases? J. Comput. Assist. Tomogr. 26: 994-999.

• Ricci P, Therneau TM, Malinchoc M, Benson JT, Petz JL, Klintmalm GB, Crippin JS, Wiesner RH, Steers JL, Rakela J, Starzl TE, Dickson ER 1997 A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology 25: 672-677. *

• Richer O, Ulinski T, Lemelle I, Ranchin B, Loirat C, Piette JC, Pillet P, Quartier P, Salomon R, Bader-Meunier B 2007 Abdominal manifestations in childhood-onset systemic lupus erythematosus. Ann. Rheum. Dis. 66: 174-178. *

• Riggio O, Efrati C, Catalano C, Pediconi F, Mecarelli O, Accornero N, Nicolao F, Angeloni S, Masini A, Ridola L, Attili AF, Merli M 2005 High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 42: 1158-1165. *

• Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM 2000 Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J. Hepatol. 32: 142-153. *

• Rochman J, Chaimovitz C, Eidelman S, Better OS 1977 Renal handling of sodium, water and divalent ions in patients with primary biliary cirrhosis. Adv. Exp. Med. Biol. 81: 121-129.

• Rockey DC 2003 Update on treatment of portal hypertension. 54th Annual Meeting of the American Association for the Study of Liver Diseases.

• Roll J, Boyer JL, Barry D, Klatskin G 1983 The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N. Engl. J. Med. 308: 1-7.

• Roulot D, Degott C, Chazouilleres O, Oberti F, Cales P, Carbonell N, Benferhat S, Bresson-Hadni S, Valla D 2004 Vascular involvement of the liver in Turner's syndrome. Hepatology 39: 239-247. *

• Ruiz Montes F, Rene Espinet JM, Rubio Caballero M 1992 Eosinophilic gastroenteritis: review of the published cases in Spain and comparison with foreign literature. Rev. Esp. Enferm. Dig. 81: 270-279.

• Russo MW, Brown RS Jr 2003 Ethical issues in living donor liver transplantation. Curr. Gastroenterol. Rep. 5: 26-30.

• Russo MW, Sood A, Jacobson IM, Brown RS Jr 2003 Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am. J. Gastroenterol. 98: 2521-2527. *

• Rydning A, Schrumpf E, Abdelnoor M, Elgjo K, Jenssen E 1990 Factors of prognostic importance in primary biliary cirrhosis. Scand. J. Gastroenterol. 25: 119-126.

• Ryu RK, Durham JD, Krysl J, Shrestha R, Shrestha R, Everson GT, Stephens J, Kam I, Wachs M, Kumpe DA 1999 Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. J. Vasc. Interv. Radiol. 10: 799-805.

• Saadeh S, Davis GL 2004 Management of ascites in patients with end-stage liver disease. Rev. Gastroenterol. Disord. 4: 175-185.

• Sahar T, Brezis M, Soares-Weiser K 2004 Antibiotic prophylaxis for bacterial infections in cirrhotic patients with ascites. Cochrane Database Syst. Rev. 2: CD004791. *

• Said A, Einstein M, Lucey MR 2007 Liver transplantation: an update 2007. Curr. Opin. Gastroenterol. 23: 292-298.

• Salerno F, Cazzaniga M 2004 TIPS versus paracentesis for the treatment of refractory ascites. Hepatology 40: 1476-1477. *

• Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, Nicolini A, Salvatori F 2004 Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40: 629-635. *

• Sanchez E, Such J, Teresa Chiva M, Soriano G, Llovet T, Merce J, Sancho F, Munoz C, Song XY, Perez-Mateo M, Balanzo J, Guarner C 2007 Development of an experimental model of induced bacterial peritonitis in cirrhotic rats with or without ascites. Am. J. Gastroenterol. 102: 1230-1236. *

• Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH 1992 Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 15: 215-221.

• Sandhu BS, Sanyal AJ 2005 Management of ascites in cirrhosis. Clin. Liver Dis. 9: 715-732.

• Santos J, Junquera F, de Torres I, Molero X, Vilaseca J, Malagelada JR 1995 Eosinophilic gastroenteritis presenting as ascites and splenomegaly. Eur. J. Gastroenterol. Hepatol. 7: 675-678.

• Sanyal AJ 2005 Pros and cons of TIPS for refractory ascites. J. Hepatol. 43: 924-925. *

• Sari R, Yildirim B, Sevinc A, Bahceci F, Hilmioglu F 2002 Gallbladder contractility in patients with cirrhotic versus malignant ascites. J. Clin. Ultrasound 30: 477-480. *

• Sarin SK, Monga R, Sandhu BS, Sharma BC, Sakhuja P, Malhotra V 2006 Primary biliary cirrhosis in India. Hepatobiliary Pancreat. Dis. Int. 5: 105-109. *

• Savidou I, Deutsch M, Soultati AS, Koudouras D, Kafiri G, Dourakis SP 2006 Hepatotoxicity induced by cyproterone acetate: a report of three cases. World J. Gastroenterol. 12: 7551-7555. *

• Schiano TD, Bodian C, Schwartz ME, Glajchen N, Min AD 2000 Accuracy and significance of computed tomographic scan assessment of hepatic volume in patients undergoing liver transplantation. Transplantation 69: 545-550.

• Scholz DG, Nagorney DM, Lindor KD 1989 Poor outcome from peritoneovenous shunts for refractory ascites. Am. J. Gastroenterol. 84: 540-543.

• Schumann M, Preiss JC, Loddenkemper C, Günther U, Somasundaram R, Siegmund B, Zeitz M 2008 Nodular regenerative hyperplasia: a side effect of azathioprine in a patient with Crohn's disease. Dtsch. Med. Wochenschr. 133: 1897-1900.

• Schuppan D, Jia JD, Brinkhaus B, Hahn EG 1999 Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30: 1099-1104. *

• Schweizer M, Schweizer P, Knupfer R, Dietz K 1992 Extrahepatic bile duct atresia. Comparison of surgical and non-surgical therapy. Monatsschr. Kinderheilkd. 140: 422-425.

• Scolapio JS, Ukleja A, McGreevy K, Burnett OL, O'Brien PC 2002 Nutritional problems in end-stage liver disease: contribution of impaired gastric emptying and ascites. J. Clin. Gastroenterol. 34: 89-93.

• Sebastian S, Tuite D, Crotty P, Torreggiani W, Buckley MJ 2004 Painful ascites. Gut 53: 1344. *

• Selimoglu MA, Ertekin V, Turkan Y, Akcay F 2007 Serum nitric oxide levels in children with Wilson's disease. Int. J. Clin. Pract. 61: 1530-1534.

• Selvaggi G, Weppler D, Nishida S, Moon J, Levi D, Kato T, Tzakis AG 2007 Ten-year experience in porto-caval hemitransposition for liver transplantation in the presence of portal vein thrombosis. Am. J. Transplant. 7: 454-460. *

• Sema K, Takei M, Uenogawa K, Horikoshi A, Hosokawa Y, Matsuda M, Henmi A, Sawada S 2005 Felty's syndrome with chronic hepatitis and compatible autoimmune hepatitis: a case presentation. Intern. Med. 44: 335-341. *

• Senzolo M, Germani G, Cholongitas E, Burra P, Burroughs AK 2007 Veno-occlusive disease: update on clinical management. World J. Gastroenterol. 13: 3918-3924. *

• Sevenet F, Capron JP 1986 Asymptomatic forms of primary biliary cirrhosis seen in 10 years in Picardie. Presse. Med. 15: 1957-1960.

• Sherlock S, Shaldon S 1963 The aetiology and management of ascites in patients with hepatic cirrhosis: a review. Gut 4: 95-105. *

• Shigeto T, Yokoyama Y, Xin B, Mizunuma H 2007 Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer. Oncol. Rep. 18: 833-840.

• Shimada M, Ijichi H, Yonemura Y, Harada N, Shiotani S, Ninomiya M, Terashi T, Yoshizumi T, Soejima Y, Suehiro T, Maehara Y 2004 The impact of splenectomy or splenic artery ligation on the outcome of a living donor adult liver transplantation using a left lobe graft. Hepatogastroenterology 51: 625-629.

• Shneider BL, Neimark E, Frankenberg T, Arnott L, Suchy FL, Emre S 2005 Critical analysis of the pediatric end-stage liver disease scoring system: a single center experience. Liver Transpl. 11: 788-795. *

• Siciliano M, Milani A, Marra L, Arringoli D, Rossi L 1986 Serum bile acids in cirrhosis: correlation with liver function parameters and with the severity of the disease. Quad. Sclavo. Diagn. 22: 355-361.

• Siller-Lopez F, Sandoval A, Salgado S, Salazar A, Bueno M, Garcia J, Vera J, Galvez J, Hernandez I, Ramos M, Aguilar-Cordova E, Armendariz-Borunda J 2004 Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 126: 1122-1133. *

• Silveira MG, Talwalkar JA, Angulo P, Lindor KD 2007 Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am. J. Gastroenterol. 102: 1244-1250. *

• Singh N, Husain S, De Vera M, Gayowski T, Cacciarelli TV 2004 Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore) 83: 188-192.

• Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H 2007 Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol. 7: 34. *

• Spahr L, Bresson-Hadni S, Amann P, Kern I, Golaz O, Frossard JL, Hadengue A 2007 Allopurinol, oxidative stress and intestinal permeability in patients with cirrhosis: an open-label pilot study. Liver Int. 27: 54-60. *

• Squires RH 2001 End-stage liver disease in children. Curr. Treat. Options Gastroenterol. 4: 409-421.

• Stewart CA, Wertheim J, Olthoff K, Furth EE, Brensinger C, Markman J, Shaked A 2004 Ascites after liver transplantation - a mystery. Liver Transpl. 10: 654-660. *

• Stoffel EM, Spigel DR, Grace ND 2004 Waldenstrom's macroglobulinemia presenting as new-onset ascites. J. Hepatol. 41: 689-690. *

• Strassburg CP, Manns MP 2006 Approaches to liver biopsy techniques-revisited. Semin. Liver Dis. 26: 318-327.

• Struben VM, Hespenheide EE, Caldwell SH 2000 Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am. J. Med. 108: 9-13. *

• Sudan DL, Shaw BW Jr 1997 The role of liver transplantation in the management of portal hypertension. Clin. Liver Dis. 1: 115-120, xii.

• Summerskill WH, Clowdus BF 2nd, Rosevear JW 1961 Long-term medical management and complications of 'resistant' ascites. Gut 2: 285-296. *

• Sun J, Li Y, Sun Y, Yu M, Feng J, Shen B 2006 Preparation and characterization of a monoclonal antibody against human B lymphocyte stimulator. Hybridoma (Larchmt.) 25: 80-85.

• Surrenti C, Pozzi M, Biagini MR, Franco C, Lombardo R, Avanzi G 1990 Effects of plasma exchange (PE) in primary biliary cirrhosis (PBC). A pilot study. Hepatogastroenterology 37: 128-130.

• Suzuki T, Suzuki T, Shinoda M, Takashi H, Yamaguchi H, Murayama M, Kamiya T, Morise K, Tashiro K, Kimura M, Yamagishi S, Ando T, Goto H 2007 An autopsy case of colon cancer associated ulcerative colitis complicated focal squamous cell carcinoma. Nippon Shokakibyo Gakkai Zasshi 104: 684-689.

• Tai YG, Liu JD, Lin KY, Chang JG, Wang CK, Siauw CP, Chen PH 1990 Eosinophilic gastroenteritis with eosinophilic ascites: report of a case. J. Formos. Med. Assoc. 89: 901-904.

• Talley NJ, Shorter RG, Phillips SF, Zinsmeister AR 1990 Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut 31: 54-58. *

• Talwalkar JA 2003 An evidence-based approach to studies in cirrhosis and portal hypertension: medical management of mild to moderate ascites. Clin. Gastroenterol. Hepatol. 1: 474-479. *

• Tanaka H, Kageyama K, Kimura M, Iwamoto SI, Ueno Y, Asagi K, Asada R, Miwa N 2006 Promotive effects of hyperthermia on the inhibition of DNA synthesis in ehrlich ascites tumor cells by eicosapentaenoic and docosahexaenoic acids. Exp. Oncol. 28: 203-208.

• Tanaka K, Ogura Y 2004 "Small-for-size graft" and "small-for-size syndrome" in living donor liver transplantation. Yonsei Med. J. 45: 1089-1094. *

• Tassoni JP Jr, Fawaz KA, Johnston DE 1991 Cirrhosis and portal hypertension in a patient with adult Niemann-Pick disease. Gastroenterology 100: 567-569.

• Tekin F, Vatansever S, Ozutemiz O, Musoglu A, Ilter T 2005 Severe exudative ascites as an initial presentation of Crohn's disease. Turk. J. Gastroenterol. 16: 171-173. *

• Therapondos G, Hol L, Benjaminov F, Wong F 2006 The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. Hepatology 44: 640-649. *

• Thoeni RF, Cello JP 2006 CT imaging of colitis. Radiology 240: 623-638. *

• Thomas M, Caroli J 1971 Polycythemia and Budd-Chiari syndrome. Apropos of 17 cases. Ann. Med. Interne (Paris) 122: 1175-1186.

• Tomei E, Diacinti D, Marini M, Mastropasqua M, Di Tola M, Sabbatella L, Picarelli A 2005 Abdominal CT findings may suggest coeliac disease. Dig. Liver Dis. 37: 402-406.

• Tomei E, Semelka RC, Braga L, Laghi A, Paolantonio P, Marini M, Passariello R, Di Tola M, Sabbatella L, Picarelli A 2006 Adult celiac disease: what is the role of MRI? J. Magn. Reson. Imaging 24: 625-629.

• Tox U, Goeser T 2005 Therapy of complications of hepatic cirrhosis. Schweiz. Rundsch. Med. Prax. 94: 727-733.

• Tran TT 2003 Liver transplantation: a clinical update. 54th Annual Meeting of the American Association for the Study of Liver Diseases.

• Trotter JF, Brimhall B, Arjal R, Phillips C 2004 Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl. 10: 995-1000. *

• Trotter JF, Suhocki PV, Rockey DC 1998 Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score. Am. J. Gastroenterol. 93: 1891-1894. *

• Tsiaousi ET, Hatzitolios AI, Trygonis SK, Savopoulos CG 2008 Malnutrition in end stage liver disease: recommendations and nutritional support. J. Gastroenterol. Hepatol. 23: 527-533. *

• Turkcapar N, Ozyuncu N, Cinar K, Ensari A, Kucuk O, Idilman R, Duman N, Ozden A 2006 A case of systemic lupus erythematosus presenting with protein-losing enteropathy. Turk. J. Gastroenterol. 17: 226-230. *

• Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J 2006 Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am. J. Gastroenterol. 101: 506-512. *

• Uchida Y, Watanabe M 1993 Plasma endothelin-1 concentrations are elevated in acute hepatitis and liver cirrhosis but not in chronic hepatitis. Gastroenterol. Jpn. 28: 666-672.

• Uriz J, Gines P, Ortega R, Jimenez W, Cardenas A, Calahorra B, Sort P, Fernandez J, Bataller R, Arroyo V, Rivera F, Rodes J 2002 Increased plasma levels of neuropeptide Y in hepatorenal syndrome. J. Hepatol. 36: 349-355. *

• Usui M, Isaji S, Das BC, Kobayashi M, Osawa I, Iida T, Sakurai H, Tabata M, Yorifuji T, Egawa H, Uemoto S 2008 Liver retransplantation with external biliary diversion for progressive familial intrahepatic cholestasis type 1: a case report. Pediatr. Transplant. Sep 10 [Epub ahead of print].

• Valentini P, Ausili E, Schiavino A, Angelone DF, Focarelli B, De Rosa G, Ranno O 2008 Acute cholestasis: atypical onset of Kawasaki disease. Dig. Liver Dis. 40: 582-584.

• Valera JM, Nei Lu C, Smok G, Fernandez M, Regonesi C, Brahm J 2004 Hepatic veno-occlusive disease, idiopathic ulcerative colitis and portal thrombosis. Report of one case. Rev. Med. Chil. 132: 1091-1095.

• Valeriano V, Funaro S, Lionetti R, Riggio O, Pulcinelli G, Fiore P, Masini A, De Castro S, Merli M 2000 Modification of cardiac function in cirrhotic patients with and without ascites. Am. J. Gastroenterol. 95: 3200-3205. *

• Valla DC 2002 Hepatic vein thrombosis (Budd-Chiari syndrome). Semin. Liver Dis. 22: 5-14.

• Van Bodegraven AA, Pena AS 2003 Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 201-212.

• van Dam GM, Gips CH, Reisman Y, Maas KW, Purmer IM, Huizenga JR, Verbaan BW 1999 Major clinical events, signs and severity assessment scores related to actual survival in patients who died from primary biliary cirrhosis. A long-term historical cohort study. Hepatogastroenterology 46: 108-115.

• Van Erpecum KJ 2006 Ascites and spontaneous bacterial peritonitis in patients with liver cirrhosis. Scand. J. Gastroenterol. Suppl. 243: 79-84. *

• van Hoogstraten HJ, Wolfhagen FH, verg PC, Kuiper H, Nix GA, Becx MC, Hoek AC, van Houte DP, Rijk MC, Salemans JM, Scherpenisse J, Schrijver M, Smit AM, Spoelstra P, Stadhouders PH, Tan TG, Hop WC, ten Kate FJ, vanBerge-Henegouwen GP, et al 1998 Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J. Hepatol. 29: 417-423. *

• van Leeuwen DJ, Sood G, Ferrante D, Lazenby AJ, Sellers MJ 2002 A 38-year-old African-American woman with an unusually rapid progression of "Primary Biliary Cirrhosis": a missed opportunity! Semin. Liver Dis. 22: 395-406.

• Vannozzi G, Tozzi A, Chibbaro G, Mello G, Ponzalli M 2008 Hepatic and mesenteric sarcoidosis without thoracic involvement: a case of severe noncirrhotic portal hypertension and successful pregnancy. Eur. J. Gastroenterol. Hepatol. 20: 1032-1035.

• Vasta F, Luca A, Miraglia R, Spada M, Gruttadauria S, Verzaro R, Cintorino D, Mandala L, Arcadipane A, Vizzini G, Gridelli B 2005 Transjugular intrahepatic portosystemic shunt in adult liver recipient with delayed graft function. Transplant. Proc. 37: 2626-2628. *

• Verhave JC, van Altena R, Wijnands MJ, Roerdink HT 2008 Tuberculous peritonitis during infliximab therapy. Neth. J. Med. 66: 77-80. *

• Vignes S, Bellanger J 2008 Primary intestinal lymphangiectasia (Waldmann's disease). Orphanet J. Rare Dis. 3: 5. *

• Vogel Y, Bous JC, Winnekendonk G, Henning BF 2008 Tuberculous peritonitis in a German patient with primary biliary cirrhosis: a case report. J. Med. Case Reports 2: 32. *

• Wallace JD, Abbott-Johnson WJ, Crawford DH, Barnard R, Potter JM, Cuneo RC 2002 GH treatment in adults with chronic liver disease: a randomized, double-blind, placebo-controlled, cross-over study. J. Clin. Endocrinol. Metab. 87: 2751-2759. *

• Wang ZG, Zhang FJ, Li QX, Meng QY 2004 Management of Budd-Chiari syndrome: what is the best approach? J. Gastroenterol. Hepatol. 19: S212-S218. *

• Watanabe N, Sugimoto N, Matsushita A, Maeda A, Nagai K, Hanioka K, Takahashi T 2003 Association of intestinal malignant lymphoma and ulcerative colitis. Intern. Med. 42: 1183-1187. *

• Wiesner RH, Porayko MK, Hay JE, LaRusso NF, Steers JL, Krom RA, Dickson ER 1996 Liver transplantation for primary sclerosing cholangitis: impact of risk factors on outcome. Liver Transpl. Surg. 2: 99-108.

• Wilkinson SP, Smith IK, Williams R 1979 Changes in plasma renin activity in cirrhosis: a reappraisal based on studies in 67 patients and "low-renin" cirrhosis. Hypertension 1: 125-129.

• Witteman BJ, Weterman IT, Griffioen G, Lamers CB 1991 Intestinal obstruction caused by non-absorbable tablets and Budd-Chiari syndrome in a patient with Crohn's disease. Ned. Tijdschr. Geneeskd. 135: 766-769.

• Wong F 2006 The use of TIPS in chronic liver disease. Ann. Hepatol. 5: 5-15. *

• Wong F 2005 Portopulmonary hypertension in cirrhosis: the pathogenetic challenge. Gut 54: 309. *

• Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M; International Ascites Club 2005 Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 54: 718-725. *

• Wong F, Liu P, Blendis L 2001 Sodium homeostasis with chronic sodium loading in preascitic cirrhosis. Gut 49: 847-851. *

• Wright AS, Rikkers LF 2005 Current management of portal hypertension. J. Gastrointest. Surg. 9: 992-1005.

• Xu P, Zhou XJ, Chen LQ, Chen J, Xie Y, Lv LH, Hou XH 2007 Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis. World J. Gastroenterol. 13: 1983-1988. *

• Yagi S, Iida T, Taniguchi K, Hori T, Hamada T, Fujii K, Mizuno S, Uemoto S 2005 Impact of portal venous pressure on regeneration and graft damage after living-donor liver transplantation. Liver Transpl. 11: 68-75. *

• Yamasaki S, Origuchi T, Nakata K, Toriyama K, Taguchi T, Ida H, Kawakami A, Eguchi K 2004 Autoimmune hepatitis in a patient with systemic lupus erythematosus: a case report. Mod. Rheumatol. 14: 169-173.

• Yao D, Xie W, Wang L 2002 Clinical analysis of 22 patients with primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 10: 344-345.

• Yawn BP, Wollan P, Gazzuola L, Kim WR 2002 Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J. Fam. Pract. 51: 135-140.

• Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F, Mizunuma H 2007 Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol. Cancer Ther. 6: 1379-1386. *

• Yoneyama K, Miyagishi K, Kiuchi Y, Shibata M, Mitamura K 2002 Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. J. Gastroenterol. 37: 1028-1034. *

• Yoo HY, Edwin D, Thuluvath PJ 2003 Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites. Am. J. Gastroenterol. 98: 1395-1399. *

• Yoo HY, Thuluvath PJ 2005 Short-term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States. Liver Int. 25: 536-541. *

• Yu JW, Wang GQ, Zhao YH, Sun LJ, Wang SQ, Li SC 2007 The MELD scoring system for predicting prognosis in patients with severe hepatitis after plasma exchange treatment. Hepatobiliary Pancreat. Dis. Int. 6: 492-496.

• Zaman A, Hapke R, Flora K, Rosen HR, Benner K 1999 Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am. J. Gastroenterol. 94: 3292-3296. *

• Zapata-Colindres J, Montano-Loza A, Zepeda-Gomez S, Uscanga L 2006 Predictive factors for portal hypertension in patients with primary sclerosing cholangitis. Gastroenterol. Hepatol. 29: 7-10.

• Zelawski W, Witalinska-Labuzek J, Stadnicki A 2005 A role of kallikrein-kinin system in gut diseases. Wiad. Lek. 58: 331-334.

• Zeuzem S 2000 Gut-liver axis. Int. J. Colorectal Dis. 15: 59-82. *

• Zhang XP, Chen L, Hu QF, Tian H, Xu RJ, Wang ZW, Wang KY, Cheng QH, Yan W, Li Y, Li QY, He Q, Wang F 2007 Effects of large dose of dexamethasone on inflammatory mediators and pancreatic cell apoptosis of rats with severe acute pancreatitis. World J. Gastroenterol. 13: 5506-5511. *

• Zhang XP, Ye Q, Jiang XG, Ma ML, Zhu FB, Zhang RP, Cheng QH 2007 Preparation method of an ideal model of multiple organ injury of rat with severe acute pancreatitis. World J. Gastroenterol. 13: 4566-4573. *

Number of references = 439

www psc-literature.org